Search Result

Results for "

Histone Demethylase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	HDAC (3) Histone Demethylase (48) Histone Methyltransferase (2) Apoptosis (5) CMV (1) Endogenous Metabolite (8) Estrogen Receptor/ERR (1) HSV (1) MDM-2/p53 (1) Mitochondrial Metabolism (4) Monoamine Oxidase (1) TNF Receptor (1)
By Research Areas:	Cancer (50) Cardiovascular Disease (1) Inflammation/Immunology (3) Neurological Disease (1)

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Targets Recommended: Histone Demethylase Histone Methyltransferase Histone Acetyltransferase HDAC

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W015114

L-2-Hydroxyglutaric acid disodium (S)-2-Hydroxyglutaric acid disodium	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit **histone demethylases** and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-13643

Daminozide 2 Publications Verification	Histone Demethylase	Cancer
Daminozide, a plant growth regulator, is a selective inhibitor of the human KDM2/7 histone demethylases, with IC₅₀s of 0.55, 1.5 and 2.1 μM for PHF8, KDM2A, and KIAA1718, respectively. Daminozide has >100-fold selectivity for KDM2/7 subfamily versus other demethylase subfamily members tested .

HY-139348

PFI-90	Histone Demethylase Apoptosis	Cancer
PFI-90 is a selective inhibitor of histone demethylase (KDM3B) that inhibits PAX3-FOXO1 action. PFI-90 induces apoptosis and myogenic differentiation, resulting in the cell death increased. PFI-90 has the potential for the antitumor activity. (patent WO2021101929A1).

HY-W017132

2,4-PDCA	Histone Demethylase	Cancer
2,4-PDCA (2,4 pyridine dicarboxylic acid) is a broad-spectrum inhibitor of 2OG oxygenase, including *JmjC domain-containing family of histone* demethylases (JHDMs)**. 2,4-PDCA is a target chemical in the field of bio-based plastics .

HY-113039

L-2-Hydroxyglutaric acid (S)-2-Hydroxyglutaric acid	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit **histone demethylases** and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-146670

KDM5B-IN-3	Histone Demethylase	Cancer
KDM5B-IN-3 (Compound 5) is a histone lysine specific demethylase 5B (KDM5B/JARID1B) inhibitor with an IC₅₀ of 9.32 μM. KDM5B-IN-3 can be used for the research of gastric cancer .

HY-131970

LSD1/HDAC6-IN-1	Histone Demethylase HDAC	Cancer
LSD1/HDAC6-IN-1 is an orally active dual inhibitor of *lysine specific demethylase* 1(LSD1)/Histone deacetylase 6 (HDAC6)**, with anti-tumor activity. LSD1/HDAC6-IN-1 can be used for the research of multiple myeloma (MM) .

HY-112308

NCGC00247743

1 Publications Verification

Histone Demethylase Cancer

NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.
HY-15774A

CBB1003 hydrochloride

Histone Demethylase Cancer

CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.
HY-15774

CBB1003

Histone Demethylase Cancer

CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

NCGC00247743 1 Publications Verification	Histone Demethylase	Cancer
NCGC00247743 is a histone lysine demethylase KDM4 inhibitor.

CBB1003 hydrochloride	Histone Demethylase	Cancer
CBB1003 Hcl is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

CBB1003	Histone Demethylase	Cancer
CBB1003 is a novel histone demethylase LSD1 inhibitor with IC50 of 10.54 uM.

HY-111048

Corin 1 Publications Verification	Histone Demethylase HDAC	Cancer
Corin is a dual inhibitor of histone lysine specific demethylase (LSD1) and histone deacetylase (HDAC), with a K_i(inact) of 110 nM for LSD1 and an IC₅₀ of 147 nM for HDAC1.

HY-103085

T-3775440 hydrochloride 2 Publications Verification	Histone Demethylase	Cancer
T-3775440 (hydrochloride) is an irreversible lysine-specific histone demethylase (LSD1) inhibitor with an IC₅₀ value of 2.1 nM.

HY-108706

KDM2A/7A-IN-1	Histone Demethylase	Cancer
KDM2A/7A-IN-1 is a first-in-class, selective and cell-permeable inhibitor of histone lysine demethylases KDM2A/7A, with an IC₅₀ of 0.16 μM for KDM2A, exhibits 75 fold selevtivity over other JmjC lysine demethylases, and is inactive on methyl transferases, and histone acetyl transferases .

HY-148807

Zavondemstat QC8222 free base; TACH 101 free base	Histone Demethylase	Cancer
Zavondemstat (QC8222; TACH 101) is an inhibitor of histone lysine demethylase 4D (KDM4D) with antineoplastic activity .

HY-122746

E67-2	Histone Methyltransferase	Cancer
E67-2, as the E67 derivative, is a low-toxicity, selective KIAA1718 Jumonji domain inhibitor with an IC₅₀ value of 3.4 µM. E67-2 selectively inhibits histone H3 lysine 9 (H3K9) Jumonji demethylase as well as histone H3 lysine 4 (H3K4) demethylase .

HY-139560

KDM2B-IN-1

Histone Demethylase Inflammation/Immunology Cancer

KDM2B-IN-1 is a histone demethylase (kdm2b) inhibitor and can be used for hyperproliferative diseases research .

KDM2B-IN-1	Histone Demethylase	Inflammation/Immunology Cancer
KDM2B-IN-1 is a histone demethylase (kdm2b) inhibitor and can be used for hyperproliferative diseases research .

HY-148807A

Zavondemstat L-lysine QC8222; TACH 101	Histone Demethylase	Cancer
Zavondemstat (QC8222; TACH 101) (L-lysine) is an inhibitor of histone lysine demethylase 4D (KDM4D) with antineoplastic activity .

HY-112623

Vafidemstat 1 Publications Verification ORY-2001	Histone Demethylase Monoamine Oxidase	Neurological Disease
Vafidemstat (ORY-2001) is an oral, brain penetrant, dual lysine-specific histone demethylase (LSD1)/MAO-B inhibitor .

HY-19612B

DDP-38003 trihydrochloride	Histone Demethylase	Cancer
DDP-38003 trihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM.

HY-19612A

DDP-38003 dihydrochloride

DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM .
HY-101928

KDM4D-IN-1

1 Publications Verification

Histone Demethylase Cancer

KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC₅₀ value of 0.41±0.03 μM.

DDP-38003 dihydrochloride
DDP-38003 dihydrochloride is an novel, orally available inhibitor of histone lysine-specific demethylase 1A (KDM1A/LSD1) with an IC₅₀ of 84 nM .

KDM4D-IN-1 1 Publications Verification	Histone Demethylase	Cancer
KDM4D-IN-1 is a new histone lysine demethylase 4D (KDM4D) inhibitor with an IC₅₀ value of 0.41±0.03 μM.

HY-12725

ML324 5+ Cited Publications	Histone Demethylase HSV CMV	Cancer
ML324 is a potent JMJD2 demethylase inhibitor with antiviral activity. ML324 also exhibits inhibition for the histone demethylase KDM4B, with an IC₅₀ of 4.9 μM. ML324 has potent anti-viral activity against both herpes simplex virus (HSV) and human cytomegalovirus (hCMV) infection via inhibition viral IE gene expression .

HY-113038B

α-Hydroxyglutaric acid 2-Hydroxyglutarate; 2-Hydroxyglutaric acid; 2-Hydroxypentanedioic acid	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid (2-Hydroxyglutarate) is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including **histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases** .

HY-139600

KDM2B-IN-3	Histone Demethylase	Cancer
KDM2B-IN-3 is a histone demethylase KDM2B inhibitor extracted from patent WO2016112284A1, compound 183c. KDM2B-IN-3 can be used for the research of cancer .

HY-139601

KDM2B-IN-4	Histone Demethylase	Cancer
KDM2B-IN-4 is a histone demethylase KDM2B inhibitor extracted from patent WO2016112284A1, compound 182b. KDM2B-IN-4 can be used for the research of cancer .

HY-113038A

α-Hydroxyglutaric acid disodium 2-Hydroxyglutarate disodium; 2-Hydroxyglutaric acid disodium; 2-Hydroxypentanedioic acid disodium	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including **histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases** .

HY-100859

LSD1-IN-5
LSD1-IN-5 (Compound 4e) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 121 nM. LSD1-IN-5 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 .

HY-100860

LSD1-IN-6	Histone Demethylase	Cancer
LSD1-IN-6 (Compound 4m) is a potent and reversible inhibitor of lysine-specific demethylase 1 (LSD1), with an IC₅₀ of 123 nM. LSD1-IN-6 increases dimethylated Lys4 of histone H3, shows no effect on expression of LSD1 .

HY-139561

KDM2B-IN-2	Histone Demethylase	Inflammation/Immunology Cancer
KDM2B-IN-2, a potent histone demethylase (kdm2b) inhibitor with an IC₅₀ of 0.021 μM in a KDM2B TR-FRET assay. KDM2B-IN-2 can be used for hyperproliferative diseases research .

HY-13953

JIB-04 Maximum Cited Publications 11 Publications Verification	Histone Demethylase Apoptosis	Cancer
JIB-04 is a pan-selective Jumonji histone demethylase inihibitor with IC₅₀s of 230, 340, 855, 445, 435, 1100, and 290 nM for JARID1A, JMJD2E, JMJD3, JMJD2A, JMJD2B, JMJD2C, and JMJD2D, respectively.

HY-113039R

L-2-Hydroxyglutaric acid (Standard) (S)-2-Hydroxyglutaric acid (Standard)	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid (Standard) is the analytical standard of L-2-Hydroxyglutaric acid. This product is intended for research and analytical applications. L-2-Hydroxyglutaric acid is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid can inhibit **histone demethylases** and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-W015114R

L-2-Hydroxyglutaric acid disodium (Standard) (S)-2-Hydroxyglutaric acid disodium (Standard)	Histone Demethylase Mitochondrial Metabolism Endogenous Metabolite	Cancer
L-2-Hydroxyglutaric acid (disodium) (Standard) is the analytical standard of L-2-Hydroxyglutaric acid (disodium). This product is intended for research and analytical applications. L-2-Hydroxyglutaric acid disodium is an epigenetic modifier and putative oncometabolite in renal cancer. L-2-Hydroxyglutaric acid disodium can inhibit **histone demethylases** and hence promote histone methylation . L-2-Hydroxyglutaric acid inhibits mitochondrial creatine kinase (Mi-CK) activity with K_m and K_i of 2.52 mM and 11.13 mM, respectively .

HY-101451

PBIT 2 Publications Verification
PBIT is a specific inhibitor of the Jumonji AT-rich Interactive Domain 1 (JARID1) enzymes. PBIT inhibits JARID1B (KDM5B or PLU1) histone demethylase with an IC₅₀ of about 3 μM . PBIT also inhibits JARID1A and JARID1C with IC₅₀s of 6 μM and 4.9 μM, respectively .

HY-107842

(Z)-JIB-04

NSC693627
Others Cancer

(Z)-JIB-04 (NSC693627) is the Z isomer of JIB-04 that has two forms, E (HY-13953) and Z isomers. (Z)-JIB-04 is inactive in epigenetic analysis .

(Z)-JIB-04 NSC693627	Others	Cancer
(Z)-JIB-04 (NSC693627) is the Z isomer of JIB-04 that has two forms, E (HY-13953) and Z isomers. (Z)-JIB-04 is inactive in epigenetic analysis .

HY-156094

JMJD3/HDAC-IN-1	HDAC Histone Demethylase Apoptosis	Cancer
JMJD3/HDAC-IN-1 (compound A5b) is a dual inhibitor targeting Jumonji domain-containing protein demethylase 3 (JMJD3) and histone deacetylase (HADC1, IC₅₀=16 nM). JMJD3/HDAC-IN-1 promotes hypermethylation of histone H3K27 and hyperacetylation of H3K9, and also cleaves caspase-7 and PARP to induce apoptosis. JMJD3/HDAC-IN-1 effectively inhibits cancer cell cloning, migration, and invasion .

HY-120400

KDM5-C70 3 Publications Verification	Histone Demethylase	Cancer
KDM5-C70 is an ethyl ester derivative of KDM5-C49 and a potent, cell-permeable and pan-KDM5 histone demethylase inhibitor. KDM5-C70 has an antiproliferative effect in myeloma cells, leading to genome-wide elevation of H3K4me3 levels .

HY-113038AS

α-Hydroxyglutaric acid-13C5 disodium 2-Hydroxyglutarate-¹³C₅ disodium; 2-Hydroxyglutaric acid-¹³C₅ sodium; 2-Hydroxypentanedioic acid-¹³C₅ disodium	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid- ¹³C₅ (sodium) is the ¹³C labeled α-Hydroxyglutaric acid sodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) sodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid sodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].

HY-146440

LSD1/ER-IN-1	Histone Demethylase Estrogen Receptor/ERR Apoptosis	Cancer
LSD1/ER-IN-1 (compound 11g) is a potent ER and LSD1 inhibitor, with an IC₅₀ of 1.55 μM (LSD1). LSD1/ER-IN-1 has high affinity selectivity for ERα protein, with α/β ratio of 7.11. LSD1/ER-IN-1 shows good antiproliferative activity against MCF-7 breast cancer cells, with an IC₅₀ of 8.79 μM .

HY-15221

Methylstat	Apoptosis Histone Demethylase MDM-2/p53	Cardiovascular Disease Cancer
Methylstat is a potent **histone demethylases inhibitor. Methylstat shows anti-proliferative activity with low cytotoxicity. Methylstat induces apoptosis and cell cycle arrest at G0/G1 phase. Methylstat increases the expression of p53** and p21 protein levels. Methylstat inhibits angiogenesis induced by various cytokines. Methylstat can be used as a chemical probe for addressing its role in angiogenesis .

HY-113038AS1

α-Hydroxyglutaric acid-d4 disodium 2-Hydroxyglutarate-d₄ disodium; 2-Hydroxyglutaric acid-d₄ disodium; 2-Hydroxypentanedioic acid-d₄ disodium	Histone Demethylase Endogenous Metabolite	Cancer
α-Hydroxyglutaric acid-d₄ (disodium) is the deuterium labeled α-Hydroxyglutaric acid disodium[1]. α-Hydroxyglutaric acid (2-Hydroxyglutarate) disodium is an α-hydroxy acid form of glutaric acid. α-Hydroxyglutaric acid disodium is a competitive inhibitor of multiple α-ketoglutarate-dependent dioxygenases, including histone demethylases and the TET family of 5-methlycytosine (5mC) hydroxylases[2].

HY-102047

KDOAM-25	Histone Demethylase	Cancer
KDOAM-25 is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-102047A

KDOAM-25 trihydrochloride	Histone Demethylase	Cancer
KDOAM-25 trihydrochloride is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 trihydrochloride increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-102047B

KDOAM-25 citrate 3 Publications Verification	Histone Demethylase	Cancer
KDOAM-25 citrate is a potent and highly selective histone lysine demethylases 5 (KDM5) inhibitor with IC₅₀s of 71 nM, 19 nM, 69 nM, 69 nM for KDM5A, KDM5B, KDM5C, KDM5D, respectively. KDOAM-25 citrate increases global H3K4 methylation at transcriptional start sites and impairs proliferation in multiple myeloma MM1S cells .

HY-150619

KDM4-IN-4	Histone Demethylase	Cancer
KDM4-IN-4 (compound 47) is a potent histone lysine demethylase 4 (KDM4) inhibitor with a modest affinity binding to ~80 μM for KDM4A-Tudor domain. KDM4-IN-4 can inhibit H3K4Me3 binding to the Tudor domain in cells with an EC₅₀ value of 105 μM. KDM4-IN-4 can be used for researching anticancer .

HY-146285

LSD1-IN-20	Histone Demethylase Histone Methyltransferase	Cancer
LSD1-IN-20 (compound 1) is a potent dual non-covalent LSD1/G9a inhibitor, with K_i values of 0.44 and 0.68 μM, respectively. LSD1-IN-20 shows antiproliferative activity in THP-1 leukemia cells and MDA-MB-231 breast cancer cells, with IC₅₀ (72 h) of 0.51 and 1.60 μM, respectively .

HY-107573

KDM2/7-IN-1 1 Publications Verification	Histone Demethylase	Cancer
KDM2/7-IN-1 (TC-E 5002) is a selective histone demethylase KDM2/7 subfamily inhibitor (IC₅₀ values are 0.2, 1.2, 6.8, 55, 83, >100 and >120 μM for KDM7A, KDM7B, KDM2A, KDM5A, KDM4C, KDM6A and KDM4A respectively). KDM2/7-IN-1 inhibits growth of HeLa and KYSE-150 cancer cells in vitro .

HY-100014

KDM5A-IN-1 2 Publications Verification	Histone Demethylase	Cancer
KDM5A-IN-1 is a potent, orally bioavailable pan-histone *lysine demethylases* 5 (KDM5) inhibitor with IC₅₀s of 45 nM, 56 nM and 55 nM for KDM5A, KDM5B and KDM5C, respectively, and with an EC₅₀ value of 960 nM for PC9 H3K4Me3. KDM5A-IN-1 is significantly less potent against other KDM5B** enzymes (1A, 2B, 3B, 4C, 6A, 7B) .

HY-151190

cis-4-Br-2,5-F2-PCPA S1024	Histone Demethylase	Cancer
cis-4-Br-2,5-F2-PCPA (S1024) is a selective inhibitor of *lysine-specific demethylase* 1 (LSD1), with a K_i value of 94 nM instead of 8.4 μM for LSD2. There is aberrant expression of LSD1 in cancer stem cells, cis-4-Br-2,5-F2-PCPA inhibits LSD1** cell proliferation and by increasing the level of dimethylated histone H3 at K4 (H3K4) in CCRF-CEM cells .

HY-143238

FY-56	Histone Demethylase	Cancer
FY-56 is a highly potent and selective LSD1/KDM1A inhibitor (IC₅₀=42 nM) and exhibits high selectivity over MAO-A/B. FY-56 induces differentiation of MOLM-13 and MV4-11 cell and has the potential for AML research .

HY-144755

MC2652	Histone Demethylase	Cancer
MC2652 (compound 1a) is a potent LSD1 inhibitor. MC2652 displays high inhibiting effects in MV4-11 and NB4 leukaemia cells. MC2652 shows antiproliferative activity against prostate cancer LNCaP cells .

Cat. No.	Product Name

HY-L024

Histone Modification Research Compound Library

614 compounds

A histone modification, a covalent post-translational modification (PTM) to histone proteins, includes methylation, phosphorylation, acetylation, ubiquitylation, and sumoylation, etc. In general, histone modifications are catalyzed by specific enzymes that act predominantly at the histone N-terminal tails involving amino acids such as lysine or arginine, as well as serine, threonine, tyrosine, etc. The PTMs made to histones can impact gene expression by altering chromatin structure or recruiting histone modifiers. Histone modifications act in diverse biological processes such as transcriptional activation/inactivation, chromosome packaging, and DNA damage/repair. Deregulation of histone modification contributes to many diseases, including cancer and autoimmune diseases.

MCE owns a unique collection of 614 bioactive compounds targeting Epigenetic Reader Domain, HDAC, Histone Acetyltransferase, Histone Demethylase, Histone Methyltransferase, Sirtuin, etc. Histone Modification Research Compound Library is a useful tool for histone modification research and drug screening.

HY-L005

Epigenetics Compound Library

1225 compounds

Epigenetics refers to changes in phenotype that are not rooted in DNA sequence. Many types of epigenetic processes have been identified, including DNA methylation, alteration in the structure of histone proteins and gene regulation by small noncoding microRNAs. Modification of DNA, protein, or RNA, resulting in changes to the function and/or regulation of these molecules, without altering their primary sequences, reveals the complexities of cellular differentiation, embryology, the regulation of gene expression, aging, cancer, and other diseases.

MCE provide a unique collection of 1225 epigenetics-related compounds that can be used in the research of the related diseases.

Cat. No.	Product Name	Target	Research Area

HY-P2509

Histone H2A (1-20)

Peptides Others

Histone H2A (1-20), a 35-residue a peptide of histone H2A, is a substrate for methyltransferase/demethylase enzymes .

HY-P2252

H3K27(Me) (15-34)	Peptides	Cancer
H3K27(Me) (15-34), a histone peptide, is a repressive chromatin markderived from human histone. Polycomb Repressive Complex 2 (PRC2) is a multiprotein complex that catalyzes the methylation of H3K27(Me) .

Species:	Human (10)
Tag:	His (5) SUMO (1) Tag Free (5) Myc (1) GST (1)
Source:	Sf9 insect cells (3) E. coli (7)

Cat. No.	Compare	Product Name	Species	Source

HY-P701616

	PHF8 Protein, Human PHF8; Histone lysine Demethylase PHF8; PHD finger protein 8; [Histone H3]-dimethyl-L-lysine(36) Demethylase PHF8; [Histone H3]-dimethyl-L-lysine(9) Demethylase PHF8	Human	E. coli
	The PHF8 protein is a histone lysine demethylase that plays a key role in cell cycle progression, rDNA transcription, and brain development. It selectively demethylates H3 'Lys-9' (H3K9Me1 and H3K9Me2), H3 'Lys-27' (H3K27Me2) and H4 'Lys-20' (H4K20Me1). PHF8 Protein, Human is the recombinant human-derived PHF8 protein, expressed by E. coli , with tag free. The total length of PHF8 Protein, Human is 446 a.a., .

HY-P701617

	PHF8 Protein, Human (His) PHF8; Histone lysine Demethylase PHF8; PHD finger protein 8; [Histone H3]-dimethyl-L-lysine(36) Demethylase PHF8; [Histone H3]-dimethyl-L-lysine(9) Demethylase PHF8	Human	E. coli
	The PHF8 protein is a histone lysine demethylase that plays a key role in cell cycle progression, rDNA transcription, and brain development. It selectively demethylates H3 'Lys-9' (H3K9Me1 and H3K9Me2), H3 'Lys-27' (H3K27Me2) and H4 'Lys-20' (H4K20Me1). PHF8 Protein, Human (His) is the recombinant human-derived PHF8 protein, expressed by E. coli , with N-6*His labeled tag. The total length of PHF8 Protein, Human (His) is 446 a.a., .

HY-P701618

	JMJD2A Protein, Human KDM4A; Lysine-specific Demethylase 4A; JmjC domain-containing Histone demethylation protein 3A; Jumonji domain-containing protein 2A; [Histone H3]-trimethyl-L-lysine(36) Demethylase 4A; [Histone H3]-trimethyl-L-lysine(9) Demethylase 4A	Human	E. coli
	The JMJD2A protein is a central histone demethylase in the histone code that specifically targets "Lys-9" and "Lys-36" of histone H3. It excludes demethylation of H3 "Lys-4", "Lys-27" and H4 "Lys-20". JMJD2A Protein, Human is the recombinant human-derived JMJD2A protein, expressed by E. coli , with tag free. The total length of JMJD2A Protein, Human is 359 a.a., .

HY-P701620

	JMJD2D Protein, Human KDM4D; Lysine-specific Demethylase 4D; JmjC domain-containing Histone demethylation protein 3D; Jumonji domain-containing protein 2D; [Histone H3]-trimethyl-L-lysine(9) Demethylase 4D	Human	E. coli
	The JMJD2D protein is a core histone demethylase in the complex histone code, specifically targeting "Lys-9" of histone H3. Importantly, it does not demethylate H3 "Lys-4", "Lys-27", "Lys-36" or H4 "Lys-20". JMJD2D Protein, Human is the recombinant human-derived JMJD2D protein, expressed by E. coli , with tag free. The total length of JMJD2D Protein, Human is 522 a.a., .

HY-P702082

	KDM6B Protein, Human (Sf9) KDM6B; Lysine-specific Demethylase 6B; JmjC domain-containing protein 3; Jumonji domain-containing protein 3; Lysine Demethylase 6B; [Histone H3]-trimethyl-L-lysine(27) Demethylase 6B	Human	Sf9 insect cells
	KDM6B protein is a histone demethylase targeting "Lys-27" of histone H3, which mainly affects the histone code. Demethylates H3 "Lys-27" to shape the epigenetic landscape. KDM6B Protein, Human (Sf9) is the recombinant human-derived KDM6B protein, expressed by Sf9 insect cells , with tag free. The total length of KDM6B Protein, Human (Sf9) is 496 a.a., .

HY-P702083

	KDM6B Protein, Human (Sf9, His) KDM6B; Lysine-specific Demethylase 6B; JmjC domain-containing protein 3; Jumonji domain-containing protein 3; Lysine Demethylase 6B; [Histone H3]-trimethyl-L-lysine(27) Demethylase 6B	Human	Sf9 insect cells
	KDM6B protein is a histone demethylase targeting "Lys-27" of histone H3, which mainly affects the histone code. Demethylates H3 "Lys-27" to shape the epigenetic landscape. KDM6B Protein, Human (Sf9, His) is the recombinant human-derived KDM6B protein, expressed by Sf9 insect cells , with N-8*His labeled tag. The total length of KDM6B Protein, Human (Sf9, His) is 496 a.a., .

HY-P75551

	LSD1 Protein, Human (sf9, His-GST) Lysine-specific Histone Demethylase 1A; KDM1A; AOF2; KDM1; KIAA0601; LSD1	Human	Sf9 insect cells
	The LSD1 protein is a histone demethylase that modifies histone H3 by demethylating “Lys-4” (H3K4me) and “Lys-9” (H3K9me). It acts as a coactivator or corepressor, oxidizing substrates via FAD to generate imines that are subsequently hydrolyzed. LSD1 Protein, Human (sf9, His-GST) is the recombinant human-derived LSD1 protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag. The total length of LSD1 Protein, Human (sf9, His-GST) is 681 a.a., with molecular weight of ~93 kDa.

HY-P701621

	KDM2A Protein, Human KDM2A; Lysine-specific Demethylase 2A; CXXC-type zinc finger protein 8; F-box and leucine-rich repeat protein 11; F-box protein FBL7; F-box protein Lilina; F-box/LRR-repeat protein 11; JmjC domain-containing Histone demethylation protein 1A; [Histone-H3]-lysine-36 Demethylase 1A	Human	E. coli
	The KDM2A protein is a histone demethylase targeting "Lys-36" of histone H3. It plays a key role in the histone code, especially the demethylation of dimethylated H3 "Lys-36". Methylation. In addition to histone demethylation, KDM2A also recognizes and binds phosphorylated proteins, promoting their ubiquitination and degradation. KDM2A Protein, Human is the recombinant human-derived KDM2A protein, expressed by E. coli , with tag free. The total length of KDM2A Protein, Human is 115 a.a., .

HY-P701622

	KDM2A Protein, Human (His) KDM2A; Lysine-specific Demethylase 2A; CXXC-type zinc finger protein 8; F-box and leucine-rich repeat protein 11; F-box protein FBL7; F-box protein Lilina; F-box/LRR-repeat protein 11; JmjC domain-containing Histone demethylation protein 1A; [Histone-H3]-lysine-36 Demethylase 1A	Human	E. coli
	The KDM2A protein is a histone demethylase targeting "Lys-36" of histone H3. It plays a key role in the histone code, especially the demethylation of dimethylated H3 "Lys-36". Methylation. In addition to histone demethylation, KDM2A also recognizes and binds phosphorylated proteins, promoting their ubiquitination and degradation. KDM2A Protein, Human (His) is the recombinant human-derived KDM2A protein, expressed by E. coli , with N-6*His labeled tag. The total length of KDM2A Protein, Human (His) is 115 a.a., .

HY-P71585

	KDM3B Protein, Human (Myc, His-SUMO) 5qNCA; C5orf7; JHDM2B; JmjC domain containing Histone demethylation protein 2B; JmjC domain-containing Histone demethylation protein 2B; jmjd1b; Jumonji domain containing 1B; Jumonji domain containing protein 1B; Jumonji domain-containing protein 1B; KDM3B; KDM3B_HUMAN; KIAA1082; Lysine (K) specific Demethylase 3B ; Lysine-specific Demethylase 3B; NET22; Nuclear protein 5qNCA	Human	E. coli
	KDM3B protein is a histone demethylase that mainly targets "Lys-9" of histone H3, catalyzes demethylation and produces formaldehyde and succinic acid by-products. In addition to histone modifications, KDM3B has been implicated in tumor suppressor activity, indicating its importance in cellular processes, gene expression regulation, and epigenetic modifications. KDM3B Protein, Human (Myc, His-SUMO) is the recombinant human-derived KDM3B protein, expressed by E. coli , with C-Myc, N-SUMO, N-His labeled tag. The total length of KDM3B Protein, Human (Myc, His-SUMO) is 224 a.a., with molecular weight of ~45.6 kDa.

Cat. No.	Product Name	Application	Reactivity

HY-P83638

KDM1B Antibody (YA3383)

AOF1; KDM1B; LSD2; Lysine-specific Histone Demethylase 1B; Lysine-specific Histone Demethylase 2
WB, ICC/IF, IP, FC Human, Mouse, Rat
HY-P83497

Mint3 Antibody (YA3242)

Histone lysine Demethylase MINA; MDIG; MINA; NO52; ROX
WB, ICC/IF Human, Mouse
HY-P82579

PHF8 Antibody (YA2324)

Histone lysine Demethylase PHF8; MRXSSD; PHD finger protein 8; PHF8; ZNF422
WB, ICC/IF, IP Human, Mouse, Rat

HY-P81319

JMJD6 Antibody (YA1064) JMJD6; KIAA0585; PTDSR; Bifunctional arginine Demethylase and lysyl-hydroxylase JMJD6; Histone arginine Demethylase JMJD6; JmjC domain-containing protein 6; Jumonji domain-containing protein 6; Lysyl-hydroxylase JMJD6; Peptide-lysine 5-diox	WB, ICC/IF	Human

HY-P82791

KDM4B Antibody (YA2536) KDM4B; JHDM3B; JMJD2B; KIAA0876; Lysine-specific Demethylase 4B; JmjC domain-containing Histone demethylation protein 3B; Jumonji domain-containing protein 2B	WB, IHC-P, ICC/IF, FC	Human, Mouse, Rat

HY-P83586

KDM4A Antibody (YA3331) KDM4A; JHDM3A; JMJD2; JMJD2A; KIAA0677; Lysine-specific Demethylase 4A; JmjC domain-containing Histone demethylation protein 3A; Jumonji domain-containing protein 2A	WB, IP	Human

HY-P80731

KDM1A Antibody (YA718) KDM1A; AOF2; KDM1; KIAA0601; LSD1; Lysine-specific Histone Demethylase 1A; BRAF35-HDAC complex protein BHC110; Flavin-containing amine oxidase domain-containing protein 2	WB	Human, Mouse, Monkey
KDM1A Antibody (YA718) is a non-conjugated and Mouse origined monoclonal antibody about 93 kDa, targeting to KDM1A (1B2). It can be used for WB assays with tag free, in the background of Human, Mouse, Monkey.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks